News
Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter
Pfizer (NYSE: PFE) stands at the top of the mountain when it comes to prescription drug sales. Last year, the big pharma company made $45.9 billion from prescription drugs, well ahead of runners-up
These 3 Charts Don't Lie: Gilead Sciences Needs an Acquisition
Pretty much everyone familiar with Gilead Sciences (NASDAQ: GILD) wants the company to make an acquisition. Many think the big biotech desperately needs one (or more) to reenergize the lethargic
Roundtable: 1 Stock I'm Never Selling
Stocks that are worth buying and holding for exceptionally long periods of time are far less common than most investors may think. Changes in underlying market conditions, after all, can knock even
5 Things You Probably Didn't Know About Veeva Systems Inc.
Few stocks have been as hot in 2017 as Veeva Systems (NYSE: VEEV). Shares of the cloud-based application provider are up more than 56% -- near the stock's all-time high set in late May. Veeva has
Is It Too Late to Get In on This Millionaire-Maker Stock?
Corcept Therapeutics (NASDAQ: CORT) is one hot biotech stock no matter how you look at it. Shares have nearly quintupled in value in just three years. So far in 2017, Corcept stock is up around 70%.
What Managed Care Organizations Are, and How Investors Can Profit From Them
Most Americans get their healthcare through a managed care organization, but nearly no one truly knows the ins and outs of the health insurance program they have. Managed care organizations are plans
Why You're Smart to Buy Vertex Pharmaceuticals Stock
You might look at Vertex Pharmaceuticals (NASDAQ: VRTX) stock and shake your head at its valuation. After soaring more than 70% so far in 2017, shares of the biotech now trade at a whopping 180 times
3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months
Although there is some truth in the saying that it takes money to make money, that doesn't mean investors can't start small and reap big rewards. With little more than $1,000 in your account, you can
Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain?
Despite a widespread rally across the biotech landscape last month, the struggling clinical-stage cancer company Celldex Therapeutics (NASDAQ: CLDX) still managed to shed 14.8% of its value in
No Surprise! Amicus Therapeutics Hits Up Investors for More Cash
Amicus Therapeutics (NASDAQ: FOLD) will be able to submit its Fabry disease drug Galafold to the FDA for consideration, a reversal of fortune that sent shares skyrocketing earlier this week. While
A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or
How Biogen Inc. Makes Most of Its Money
Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug
Here's Why Alder Biopharmaceuticals Inc Stock Is Bouncing Back
Investors in Alder Biopharmaceuticals (NASDAQ: ALDR) are having another wild day. Shares of the clinical-stage biopharma rose as much as 15.5% on Thursday after the company released the pricing
Is Juno Therapeutics Stock Still a Strong Buy?
Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) rose by a healthy 22% last month, according to S&P Global Market Intelligence. The drugmaker's shares seemed to get a lift from
Johnson & Johnson Looks for Second-Quarter Strength to Keep Upward Momentum
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) has been immensely successful over the years, and it has also done well for shareholders recently. With a nearly 15% rise so far in 2017, Johnson
Novo Nordisk – Das sieht jetzt richtig gut aus!
Heute ein kurzer Blick auf die zuletzt Starkunter Druck gekommene Aktie des Insulin-Herstellers Novo Nordisk. Nach einer deutlichen Erholung befindet sich die Aktie inzwischen wieder in einer sehr
Saschas Börsentag, Video-Börsen-Blog vom 7. Juni 2017 - heißer Börsentag?!
Ich bespreche heute die Aktien von Bayer, Volkswagen (VW), Fresenius Medical Care (FMC), Adidas, E.ON, RWE, Evonik Industries, Covestro, Steinhoff International, Stada Arzneimittel, GEA Group, Osram
Bayer-Aktie: Steht massive Kurskorrektur bevor?
Liebe Leser,
Bayer hat trotz der geplanten Milliardenübernahme von Monsanto seit Beginn des Jahres eine gute Entwicklung gezeigt. Vielleicht liegt dies auch an den zu erwartenden Synergieeffekten....
Saschas Börsentag, Video-Börsen-Blog vom 23. Mai 2017 - ich stelle mich der Kritik!!
Heute bespreche ich die Aktien von Merck KGaA, Daimler, Vonovia, Bayer, ThyssenKrupp, E.ON, Hugo Boss, Südzucker, Krones, Dürr, Uniper, Zalando, Hamborner REIT, DIC Asset, Borussia Dortmund, Wacker
Henry Schein – Ausbruch oder Doppeltop?
Liebe Leser,
zu den Aktien mit der besten Kursperformance seit Ende der Finanzkrise 2009 gehört das Papier von Henry Schein. Von rund 33 US-Dollar ging es hinauf bis auf 180 US-Dollar im....
Amgen: Blockbuster-Medikamente-Umsatz macht Anleger stutzig!
Lieber Leser,
das am Umsatz gemessen weltgrößte Biotech-Unternehmen Amgen führt insgesamt sieben Blockbuster-Medikamente, die jeweils mehr als 1 Mrd. US-Dollar jährlich an Umsatz generieren. Das....
Novo Nordisk: Eine gute Nachricht nach der anderen!
Lieber Leser,
Novo Nordisk konnte zuletzt das hohe Niveau der Vorwochen halten. Es ging innerhalb einer Woche zwar um knapp 1 % zurück, dies ist jedoch angesichts der Kurssteigerung in Höhe von 9....
Gilead Sciences: Short-Investoren freuen sich
Lieber Leser,
Gilead Sciences ist in den vergangenen Handelssitzungen recht deutlich unter die Räder gekommen. Die Aktie verlor binnen zweier Wochen annähernd 7 %. Die Kurse gingen seit....
Novo Nordisk: Der mögliche Turnaround nimmt Formen an!
Lieber Leser,
Anfang Mai hat Novo Nordisk die Zahlen für das erste Quartal vorgelegt und die Analysteneinschätzungen beim Umsatz sowie beim Ergebnis je Aktie übertroffen. Dabei lag der....
Gilead Sciences Inc.: Die Analyse!
Liebe Leser,
letzte Woche beschäftigten die Nachrichten zu Gilead Sciences die Gemüter der Anleger. Denn Clemens van Baaijen hat sich das Unternehmen und seine Aktie in einer 3-Stufen-Analyse....